drugset / Trial / NCT00790816
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to provide continued access to lapatinib as monotherapy or as part of a combination regimen to cancer subjects who are currently participating in a phase I trial that has met its study objectives.
Timeline
- Start
- 2008-10
- Primary completion
- 2016-08-19
- Completion
- 2016-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Docetaxel | Small molecule | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Letrozole | Other / unclassified | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Trastuzumab | Monoclonal antibody | — | — |